L-Citrulline in Surgery for Congenital Heart Defects

Purpose of this Study

We are doing this study to see if L-citrulline (the study drug) lessens the amount of time spent on mechanical ventilation (an automatic breathing machine) and decreases the amount of other medicines needed after surgery for congenital heart repair.

Who Can Participate?

Eligibility

Children younger than 18 who are scheduled to have cardiopulmonary bypass done at Duke to repair one of the following congenital defects:
- Large unrestrictive ventricular septal defect; OR
- Ostium primum/secundum atrial septal defect; OR
- Partial or complete atrioventricular septal defect

For more information about who can join this study, contact the study team at susan.hajmohammad@duke.edu.

Age Range

0-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

If you agree to have your child join this study, they will:
- Get a random assignment (like a coin flip) to receive the study drug or placebo (an inactive substance)
- Receive 4 doses of the study drug or placebo
- Have blood draws
- Have a phone call with the study team after they go home from the hospital

Locations

Duke University Hospital

Visit Timing

Weekdays
Weekends
Evenings

Compensation

No

Spanish Materials Available

Yes

Study Details

Full Title

A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Principal Investigator

Ziv
Beckerman

Protocol Number

PRO00112040

NCT ID

NCT05253209

Phase

III

Enrollment Status

OPEN TO ACCRUAL